Fallopian Tube Neoplasms Clinical Trials

52 clinical trials for Fallopian Tube Neoplasms across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — RECRUITING · PHASE3
• OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy — RECRUITING · NA
• Agnostic Therapy in Rare Solid Tumors — RECRUITING · PHASE2
• MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) — RECRUITING · PHASE3
• Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — RECRUITING
• BP1001-A in Patients With Advanced or Recurrent Solid Tumors — RECRUITING · PHASE1
• Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers — RECRUITING · NA
• MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm. — RECRUITING · NA
• Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery — ACTIVE_NOT_RECRUITING · PHASE3
• Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors — TERMINATED · PHASE1
• AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer — COMPLETED · PHASE4
• Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) — COMPLETED · PHASE2
• Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. — COMPLETED · PHASE1
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer — TERMINATED · PHASE1
• SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery — OTHER
• MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer — OTHER · NA
• Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer — COMPLETED · PHASE3
• HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life — OTHER
• Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy — COMPLETED
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer — OTHER · PHASE2
• Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") — COMPLETED · PHASE2
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors — COMPLETED · PHASE1
• A two-part, multicentre, international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer — OTHER
• 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant — WITHDRAWN · PHASE2
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors — COMPLETED · PHASE1
• ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma — TERMINATED · PHASE1
• A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — COMPLETED · PHASE3
• Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy — COMPLETED · NA
• Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas — COMPLETED · PHASE2
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer — TERMINATED · PHASE2
• Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients — COMPLETED · NA
• OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 — COMPLETED · PHASE2
• Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer — COMPLETED · PHASE2
• DNA Single Nucleotide Polymorphisms as Predictors of Toxicity — OTHER
• Pharmacogenomics of Paclitaxel in Ovarian Cancer — COMPLETED
• A Prospective Trial of COXEN Chemotherapy Prediction — WITHDRAWN · NA
• Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer — WITHDRAWN · PHASE2
• A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers — COMPLETED · PHASE2
• Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — TERMINATED · PHASE2
• EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer — COMPLETED · PHASE2
• Pharmacogenomics of Paclitaxel in Ovarian Cancer — COMPLETED
• An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy — COMPLETED · PHASE3
• Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer — COMPLETED · PHASE2
• A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. — COMPLETED · PHASE3
• Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients — COMPLETED · PHASE2

Refine this search